// Sep 2026
Why Isn’t One Assay Enough for Gene Editing Off-Target Safety Assessment?
One assay is not enough for gene editing off-target safety assessment because each method detects a different subset of potential edits, and off-target profiles can change by editing modality, cell type, donor context, and dose. The most comprehensive safety profiles combine biochemical, computational, and cell-based approaches, followed by deep sequencing confirmation and biological risk annotation.
Different Methods Detect Different Off-Target Events
Biochemical approaches such as Digenome-Seq help nominate potential off-target sites by testing editor activity against genomic DNA. Computational tools identify sites based on homology patterns. While both assays are useful for nominating genomic sites for further safety evaluation in a cell-free manner, a direct measure of in-cell editing activity is missing. In our assessments at ElevateBio, whole exome sequencing (WES) identifies off-target events down to 1% allele frequency. WES acts as an unbiased safety net, nominating and confirming edits across all coding regions without requiring prior knowledge of where to look.
Off-Target Profiles Can Change by Cell Type and Editing Modality
The same guide RNA and CRISPR editor can generate different off-target patterns in different cell types, for instance primary T cells versus primary hepatocytes. A nuclease and base editor using identical guides can create distinct off-target signatures. These biological variables mean that safety assessment in a single cell type or with a single detection method provides false confidence. Primary cells from both male and female donors reveal the true editing landscape that immortalized cell lines may mask.
Assessment Data Should Feed Back Into Editor Engineering
Off-target reduction happens through iterative cycles of detection and protein engineering. At ElevateBio, improvements to adenosine deaminase domains have reduced both the number of off-target sites and editing magnitude at each site. This optimization is enabled by a constant feedback loop between off-target assessment and engineering to accelerate the development of safer, more specific therapeutics.
Orthogonal Methods Turn Detection Data Into Safety Insight
Combining Digenome-Seq, computational prediction through tools like Calitas, and whole exome sequencing captures the broadest spectrum of potential off-target events. Each confirmed site undergoes clinical variant analysis using ACMG/AMP guidelines and comparison to databases of known genetic variation to determine biological risk (see the technical poster, with data). Dose-response curves in primary cells establish whether off-target editing occurs at therapeutically relevant doses. This integrated framework transforms raw detection data into risk assessments that guide both engineering decisions and regulatory submissions.
Off-target safety assessment should not rely on one assay or one model system. Programs that generate the most useful safety profiles layer orthogonal detection methods, evaluate therapeutically relevant primary cells, and use the results to guide editor engineering before IND-enabling decisions are locked.
Allie Crawley, PhD, Associate Director, Computational Biology
Allie oversees teams building applied genomics platforms in the CRISPR medicines field. She has worked to establish bioinformatic software and workflows, including design of correction strategies for genetic diseases, evaluation of editing, and off-target safety measurements for genomic medicines. After receiving her PhD in Functional Genomics from North Carolina State University, she joined AgBiome and helped build the foundational technology platform owned by ElevateBio Life Edit.
